In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Systemic therapy often results in the reduction of tumor size but rarely succeeds in
eradicating all cancer cells. Drug efflux, persistence of cancer stem cells (CSCs), epithelial …

Summary Lung cancer in East Asia is characterized by a high percentage of never-smokers,
early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this …

PURPOSE Standard first-line therapy for EGFR-mutant advanced non–small-cell lung
cancer (NSCLC) is an epidermal growth factor receptor (EGFR)–directed oral tyrosine …

The CRISPR/Cas9 system is an RNA-based adaptive immune system in bacteria and
archaea. Various studies have shown that it is possible to target a wide range of human …

Despite encouraging progress in the development of in vitro cancer models, in vitro cancer
models that simultaneously recapitulate the complexity of the tumor microenvironment and …

Simple Summary Tumor heterogeneity promotes the development of drug resistance in
cancer. HDAC inhibitors modulate several processes that contribute to intra-tumoral …

Background This study investigated the role of fibrinogen-like protein 1 (FGL1) in regulating
gefitinib resistance of PC9/GR non-small cell lung cancer (NSCLC). Methods The effect of …

Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent
class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …